Pharma Industry News

Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal with Californian medtech Vivani Medical to help.

Source: FierceBiotech

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

Leave a Comment

[mwai_chat window="true" fullscreen="true"]